Search results
Results From The WOW.Com Content Network
Lonza Group Ag (LZAGY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Lonza's adjusted core earnings before interest, taxes, depreciation and amortization (EBITDA) fell to 893 million Swiss francs ($976.4 million) in the first half of the year, from 922 million ...
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland.
The Swiss Market Index (SMI) is Switzerland's blue-chip stock market index, which makes it the most followed in the country. [2] [3] It is made up of 20 of the largest and most liquid Swiss Performance Index (SPI) stocks. [1] As a price index, the SMI is not adjusted for dividends. [4] The SMI was introduced on 30 June 1988 at a baseline value ...
The kicker: While this stock's forward-looking dividend yield of 1.2% isn't exactly thrilling, what it lacks in current yield it more than makes up for in dividend growth.
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563.
Language links are at the top of the page across from the title.
Lonza said on Tuesday it has capacity to fill syringes to serve makers of highly popular new weight-loss drugs in a class known as GLP-1, though it does not produce the active ingredient in those ...